Therapeutic Activity and Biodistribution of a Nano-Sized Polymer-Dexamethasone Conjugate Intended for the Targeted Treatment of Rheumatoid Arthritis

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22310%2F23%3A43927233" target="_blank" >RIV/60461373:22310/23:43927233 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Therapeutic Activity and Biodistribution of a Nano-Sized Polymer-Dexamethasone Conjugate Intended for the Targeted Treatment of Rheumatoid Arthritis
Original language description
Rheumatoid arthritis is a chronic inflammatory autoimmune disease caused by alteration of the immune system. Current therapies have several limitations and the use of nanomedicines represents a promising strategy to overcome them. By employing a mouse model of adjuvant induced arthritis, we aimed to evaluate the biodistribution and therapeutic effects of glucocorticoid dexamethasone conjugated to a nanocarrier based on biocompatible N-(2 hydroxypropyl) methacrylamide copolymers. We observed an increased accumulation of dexamethasone polymer nanomedicines in the arthritic mouse paw using non-invasive fluorescent in vivo imaging and confirmed it by the analysis of tissue homogenates. The dexamethasone conjugate exhibited a dose-dependent healing effect on arthritis and an improved therapeutic outcome compared to free dexamethasone. Overall, our data suggest that the conjugation of dexamethasone to a polymer nanocarrier by means of a stimuli-sensitive spacer is a suitable strategy for improving rheumatoid arthritis therapy.
Czech name
—
Czech description
—

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)